Alzchem Group Ag Stock EBITDA
ACT Stock | EUR 57.40 0.20 0.35% |
AlzChem Group AG fundamentals help investors to digest information that contributes to AlzChem Group's financial success or failures. It also enables traders to predict the movement of AlzChem Stock. The fundamental analysis module provides a way to measure AlzChem Group's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AlzChem Group stock.
AlzChem |
AlzChem Group AG Company EBITDA Analysis
AlzChem Group's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current AlzChem Group EBITDA | 62.69 M |
Most of AlzChem Group's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AlzChem Group AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition |
According to the company disclosure, AlzChem Group AG reported earnings before interest,tax, depreciation and amortization of 62.69 M. This is much higher than that of the sector and significantly higher than that of the EBITDA industry. The ebitda for all Germany stocks is notably lower than that of the firm.
Did you try this?
Run Portfolio Diagnostics Now
Portfolio DiagnosticsUse generated alerts and portfolio events aggregator to diagnose current holdings |
All Next | Launch Module |
AlzChem Fundamentals
Current Valuation | 261.71 M | |||
Price To Book | 1.35 X | |||
Price To Sales | 0.37 X | |||
Revenue | 422.29 M | |||
EBITDA | 62.69 M | |||
Net Income | 27.59 M | |||
Total Debt | 37.55 M | |||
Cash Flow From Operations | 43.02 M | |||
Market Capitalization | 249.32 M | |||
Total Asset | 377.67 M | |||
Z Score | 4.6 | |||
Annual Yield | 0.03 % | |||
Net Asset | 377.67 M | |||
Last Dividend Paid | 0.75 |
About AlzChem Group Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AlzChem Group AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AlzChem Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AlzChem Group AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for AlzChem Stock Analysis
When running AlzChem Group's price analysis, check to measure AlzChem Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AlzChem Group is operating at the current time. Most of AlzChem Group's value examination focuses on studying past and present price action to predict the probability of AlzChem Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AlzChem Group's price. Additionally, you may evaluate how the addition of AlzChem Group to your portfolios can decrease your overall portfolio volatility.